Mylan Completes $5.3 Bn Deal for Abbott’s Non-US Developed Markets BusinessesBy
Mylan N.V. and Mylan Inc. report that they have successfully completed the acquisition of Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business for approximately $5.3 billion. In July 2014, Mylan announced the deal.
Under the previously announced terms of the transaction agreement, Abbott received 110 million shares of Mylan N.V., resulting in former Mylan Inc. shareholders now owning approximately 78% of Mylan N.V., and Abbott now owning approximately 22% of Mylan N.V. Mylan Inc. and Abbott’s non-U.S. developed markets specialty and branded generics business have been reorganized under Mylan N.V., a new public company organized in the Netherlands. Mylan N.V. will be led by the former Mylan Inc. executive team. The company will trade on Nasdaq under the ticker symbol MYL.